Black women with breast cancer often deal with an uncomfortable and at times painful side effect known as neuropathy, but a ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has ...

MCCLEAN, VA, UNITED STATES, January 14, 2025 /EINPresswire / -- Perthera, a leader in AI-driven precision oncology, announces a groundbreaking adva ...

Vascarta has obtained the exclusive rights to a novel method of creating more effective cancer therapies with fewer side effects applying new and unique linker chemistry developed by the City College ...

Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in ...

Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with ...

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.

The selection and schedule of treatment should depend on patient preference and toxicity potential, according to Azka Ali, MD.

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...